Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : wla(warner lambert) -- Ignore unavailable to you. Want to Upgrade?

To: KAF who wrote (739)	5/16/1999 2:04:00 PM
From: Captain Jack	Read Replies (1) \| Respond to of 942

KAF--- In the past I agreed with you and bought up to 74+. Recently it cannot hold 70. It has ben in the mid 60s often in the recent past. Then an unsustainable run to the low 70s for a fast drop. IMO it has become a terrible investment but a wonderful money maker as a trading issue. So if by chance it does not fall from 70 - 71 and it must be held to 78 who cares but that has been the impossible dream recently... AGPH has a good pipeline and a nice relationship with IMNR. When some of the IMNR pipeline is producing that relationship will be worth tons to WLA.

To: KAF who wrote (739)	5/16/1999 3:14:00 PM
From: Captain Jack	Respond to of 942

Report: Flat drug stocks are buys By Tom Bemis, CBS MarketWatch Last Update: 2:43 PM ET May 15, 1999 NewsWatch NEW YORK (CBS.MW) -- Drug stocks, which helped power much of the bull market's run until this year, may represent a buying opportunity according to at least one analyst. Salomon Smith Barney's Jason Kolbert told Barron's Magazine the outlook for the sector remains "very, very robust." That's because as baby boomers age they are likely to keep up demand for drugs to make them feel better. Unit sales of pharmaceuticals have grown 10 percent a year for three years, Barron's reported. In addition, new drugs have seen strong growth even though they're competing against established products, suggesting that the overall market is bigger, Kolbert told the magazine. He cited Lipitor, a cholesterol drug sold by Warner Lambert (WLA: news, msgs) and Pfizer (PFE: news, msgs). It competes against similar products from Merck (MRK: news, msgs) and Bristol-Myers Squibb (BMY: news, msgs). Drug companies have increased advertising directly to consumers in a bid to boost sales. The strategy has helped pay off for Pfizer's anti-impotence drug Viagra, Merck's anti-baldness pill Propecia, and Schering-Plough's (SGP: news, msgs) anti-allergy pill Claritin. Biotech companies like Centocor (CNTO: news, msgs), Immunex (IMNX: news, msgs) and IDEC Pharmaceuticals (IDPH: news, msgs) are also coming up with new products which can help boost performance at larger drug companies that back their research or help with marketing. Kolbert told Barron's he also likes Eli Lilly (LLY: news, msgs) which has extended the patents on its blockbuster anti-depressant drug Prozac. (Barron's)